Metastatic prostate cancer rising in the US

Is the drop in PSA testing to blame for a steady increase in aggressive disease?

The rise in metastatic prostate cancer incidence, predicted by opponents of the 2012 US move away from routine PSA screening, may now be happening, researchers say.

Blood test

Harvard-led researchers used data from the National Cancer Institute's Surveillance, Epidemiology and End Results (SEER) database to examine prostate cancer incidence rates from 2010-15.

As expected, with fewer PSA tests being done, age-standardised incidence rates of localised disease, as defined by the National Comprehensive Cancer Network (NCCN) fell sharply between